Lynparza

Lynparza (olaparib) is a poly ADP-ribose polymerase (PARP) inhibitor approved to treat advanced ovarian cancer and HER2-negative metastatic breast cancer with a germline BRCA mutation.

Product Information – European Medicines Agency